Use of high flow nasal cannula in Covid 19 patients with respiratory failure

Role of High Flow Nasal Cannula (HFNC) as a treatment modality in patients with hypoxemic respiratory failure due to COVID - 19

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2021/04/032795

Enrollment

Registered

2021-04-13

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: High flow nasal cannula: A high flow nasal cannula (HFNC) system needs to have two important components in addition to providing oxygen. As it involves very high flow, it should: 1. Be

cold air will be irritating to the airway and significant heat loss can occur from the patientâ??s body. 2. It should be able to humidify the air

dry air is an irritant to the airways and dries up secretions and mucous membranes. The HFNC is thus, not a simple oxygen delivery cannula with high flows, but has some additional engineering modifica

Eligibility

Inclusion criteria

Inclusion criteria: COVID â?? 19 pneumonia (Diagnosed with polymerase chain reaction) Age more than 18 years of either gender Acute Hypoxemic Respiratory Failure Admission to intensive care unit Supported by high flow nasal cannulae

Exclusion criteria

Exclusion criteria: Intubation prior to HFNC therapy Uncooperative and neurologically (Glasgow coma scale less than equal to 12) unstable patients Patients with haemodynamic instability Patients with primary pulmonary disease, respiratory acidosis in the first blood gases (pH = 50) In all conditions where PEEP is contraindicated like in presence of pneumothorax, large bullae in lungs or haemodynamic instability. Patient not accepting nasal cannula due to irritation or discomfort

Design outcomes

Primary

Measure	Time frame
To describe the use of HFNC in COVID â?? 19 patients with acute hypoxemic respiratory failure and evaluation of ROX index over time in patients treated with HFNC.Timepoint: 6 months or cessation of COVID 19 pandemic whichever is earlier	—

Secondary

Measure	Time frame
1) Requirement of HFNC flow 2) Requirement of FiO2 3) Respiratory rate during HFNC therapy 4) Success rate of using HFNC Timepoint: 6 months or cessation of COVID 19 pandemic whichever is earlier	—

Countries

India

Contacts

Public ContactDr Devyani Desai

Maharaja sayajirao University of Baroda

devyani.dr@gmail.com9909983168

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026